Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
DICE Therapeutics, Inc. (DICE) Create: Alert

All | News | Filings
Date FiledTypeDescription
05/11/2023 8-K Quarterly results
Docs: "DICE Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights • First patient dosed in global Phase 2b clinical trial of lead oral IL-17 inhibitor, DC-806, in moderate-to-severe psoriasis • Topline data from Phase 1 clinical trial of second oral IL-17 inhibitor, DC-853, in healthy volunteers expected in 2H 2023 • Strong financial position with $554.5 million in cash, cash equivalents and marketable securities, providing runway into 2026 and through multiple expected clinical milestones SOUTH SAN FRANCISCO, CA, May 11, 2023 – DICE Therapeutics, Inc. , a biopharmaceutical company leveraging its proprietary DELSCAPE technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology, today reported fi..."
03/15/2023 8-K Quarterly results
Docs: "DICE Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights • IND application for DICE’s lead oral IL-17 antagonist, DC-806, cleared by FDA; global Phase 2b clinical trial in patients with moderate-to-severe psoriasis on track to initiate in 1H 2023 • First participants dosed in Phase 1 clinical trial of second oral IL-17 antagonist DC-853; topline data in healthy volunteers expected in 2H 2023 • Ended 2022 with $574.2 million in cash, cash equivalents and marketable securities, providing runway into 2026 and through multiple expected clinical milestones SOUTH SAN FRANCISCO, CA, March 15, 2023 – DICE Therapeutics, Inc. , a biopharmaceutical company leveraging its proprietary DELSCAPE technology platform to build a pipeline of nov..."
11/09/2022 8-K Quarterly results
Docs: "DICE Therapeutics Reports Third Quarter 2022 Financial Results and Recent Highlights • Reported positive Phase 1 proof-of-concept data supporting the further development of lead oral IL-17 antagonist, DC-806, as potential best-in-class oral agent for psoriasis • Demonstrated direct inhibition of a cytokine with a small molecule in psoriasis patients, which we believe validates the DELSCAPE platform and DICE’s approach to identifying and advancing oral medicines against protein-protein interactions in immunology • Completed $345 million upsized public offering providing funding into 2026 SOUTH SAN FRANCISCO, CA, November 9, 2022 – DICE Therapeutics, Inc. , a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therap..."
08/11/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
11/12/2021 8-K Quarterly results
Docs: "DICE Therapeutics Reports Third Quarter 2021 Financial Results and Recent Highlights"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy